Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA

  • Talamillo, A
  • Grande, L
  • Ruiz-Ontañon, P
  • Velasquez, C
  • Mollinedo, P
  • Torices, S
  • Sánchez-Gómez, Pilar
  • Aznar, A
  • Esparis-Ogando, A
  • Lopez-Lopez, C
  • Lafita, C
  • Berciano, M T
  • Montero, J A
  • Vazquez-Barquero, A
  • Segura, V
  • Villagra, N T
  • Pandiella, A
  • Lafarga, Miguel
  • Leon, J
  • Martinez-Climent, J A
  • Sanz-Moreno, V
  • Fernandez-Luna, J L
Long-term survival remains low for most patients with glioblastoma (GBM), which reveals the need for markers of disease outcome and novel therapeutic targets. We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells. Differentiation of glioblastoma stem-like cells drives the nuclear translocation of an intracellular fragment of ODZ1 through proteolytic cleavage by signal peptide peptidase-like 2a. The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo. Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells. This activity is mediated by an ODZ1-triggered transcriptional pathway, through the E-box binding Myc protein, that promotes the expression and activation of Ras homolog family member A (RhoA) and subsequent activation of Rho-associated, coiled-coil containing protein kinase (ROCK). Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice. Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival. Our findings establish a novel marker of invading GBM cells and consequently a potential marker of disease progression and a therapeutic target in GBM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evaluation of FASTinov for rapid antimicrobial susceptibility testing in Pseudomonas aeruginosa

  • Cintora Mairal, Carmen
  • Ortiz de la Rosa, José Manuel
  • Pina-Vaz, Cidália
  • Martín-Gutiérrez, Guillermo
  • Lepe, José Antonio
Pseudomonas aeruginosa is a critical priority pathogen due to its high resistance rates and limited treatment options. Rapid antimicrobial susceptibility testing (rAST) is essential to optimize therapy, particularly because resistance mechanisms in P. aeruginosa often arise from adaptive genetic expression rather than specific resistance genes. FASTinov, a flow cytometry-based rAST system, was developed to address this challenge by providing phenotypic susceptibility results within hours. In this study, we assessed FASTinov’s performance for rapid antimicrobial susceptibility testing (rAST) in 100 P. aeruginosa strains, using broth microdilution as the reference method. For clinical relevance, we also included the MicroScan WalkAway system as a comparator. FASTinov demonstrated a categorical agreement of 99% across the tested antibiotics, with particularly strong agreement for cephalosporins. Notably, FASTinov significantly reduced the time to results, delivering susceptibility data in an average of 3.15 h (CI 95% 3.13–3.17), compared to 28.88 h (CI 95% 20.71–37.04) for standard methods. Additionally, the system exhibited lower rates of major and very major errors compared to MicroScan, further reinforcing its reliability. These findings highlight FASTinov as a promising rAST system capable of providing rapid and accurate susceptibility profiles directly from bacterial colonies. Further research is warranted to evaluate its clinical impact on patient outcomes and cost-effectiveness., JMO-R. is supported by the Subprograme Sara Borrell, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spain (CD21/00098). GM-G has received funding from the Andalusia Government in the grants for human resources reinforcement in the research activity (Acción B de refuerzos de larga duración). This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI23/01760” and by national funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDP/4255/2020)., Peer reviewed